Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
New Alzheimer disease study findings reported from A. Schneeberger and co-authors
July 1st, 2009
"Based on the notion that cerebral accumulation of certain A beta species is central to AD pathogenesis and endowed with the knowledge that emerged during clinical testing of the first human Alzheimer vaccine, AN1792, we designed a new generation of Alzheimer vaccines. Rather than relying on full-length A beta itself or fragments thereof, AFFITOPE vaccines use short peptides, mimicking parts of the native A beta sequence, as their antigenic component," scientists in Vienna, Austria report. "The technology created to identify these peptides, termed AFFITOPE-technology, at the same time provides the basis for the multi-component safety concept realized in AFFITOPE...
Source: Vaccine Weekly (2009-07-01)
|
